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1  | INTRODUC TION
Kidney transplantation is the preferred modality of renal replacement 
therapy for patients with end- stage renal disease and is performed in 
nearly 100 countries. Despite its broad application, long- term graft 
failure remains an important limitation. Meier- Kriesche et al have re-
ported that kidney transplant half- life has increased only modestly in 
recent years in the United States.1
The regular reporting of posttransplantation outcomes to a cen-
tralized registry in some countries offers a unique opportunity to 
explore country- level differences on outcomes. Kim et al showed a 
49% higher risk of death beyond the first posttransplantation year 
in an 8- year cohort of United States kidney transplant recipients 
compared to a cohort of Canadians transplanted in during the same 
period.2 However, the absolute long- term risk of death after kidney 
transplantation is low, and recipients more commonly face allograft 
failure. Gondos et al reported that graft survival among various sub-
sets of European kidney transplant recipients was superior to corre-
sponding subsets in United States patients using period analysis of 
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Kidney transplant outcomes that vary by program or geopolitical unit may result from 
variability in practice patterns or health care delivery systems. In this collaborative 
study, we compared kidney graft outcomes among 4 countries (United States, United 
Kingdom, Australia, and New Zealand) on 3 continents. We analyzed transplant and 
follow- up registry data from 1988- 2014 for 379 257 recipients of first kidney- only 
transplants using Cox regression. Compared to the United States, 1- year adjusted 
graft failure risk was significantly higher in the United Kingdom (hazard ratio [HR] 
1.22, 95% confidence interval [CI] 1.18- 1.26, P < .001) and New Zealand (hazard ratio 
[HR] 1.29, 95% confidence interval [CI] 1.14- 1.46, P < .001), but lower in Australia 
(HR 0.90, 95% CI 0.84- 0.96, P = .001). In contrast, long- term adjusted graft failure 
risk (conditional on 1- year function) was significantly higher in the United States 
compared to Australia, New Zealand, and the United Kingdom (HR 0.74, 0.75, and 
0.74, respectively; each P < .001). Thus long- term kidney graft outcomes are approxi-
mately 25% worse in the United States than in 3 other countries with well- developed 
kidney transplant systems. Case mix differences and residual confounding from un-
measured factors were found to be unlikely explanations. These findings suggest 
that identification of potentially modifiable country- specific differences in care deliv-
ery and/or practice patterns should be sought.
K E Y W O R D S
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data submitted voluntarily to the Collaborative Transplant Study.3 
Country outcomes within Europe were not analyzed.
The overall effectiveness of well- established kidney transplant 
systems, using graft failure as the outcome of interest, has not been 
studied at a country level. Rather than undertake an individual pa-
tient data meta- analysis, the opportunity to use detailed patient- 
level longitudinal data from transplants performed over the last 
quarter century in 4 countries on 3 continents and reported to regis-
tries with robust data tracking, motivated us to perform a study with 
the overarching goal to determine the existence and magnitude of 
country- level differences in kidney graft outcome.
2  | MATERIAL S AND METHODS
Patient- level data were combined from 3 transplant registries cover-
ing 4 countries on first single- organ kidney transplants from 1988 
through 2014, with follow- up through 2014. We obtained data from 
the Scientific Registry of Transplant Recipients (SRTR) for the United 
States, the National Health Service Blood and Transplant for the 
United Kingdom (NHSBT), and the Australia and New Zealand Dialysis 
and Transplant (ANZDATA) Registry for Australia and New Zealand.
Baseline recipient, donor, and transplant variables were harmo-
nized across the 3 data sources prior to analysis. Ascertainment of 
graft failure, defined as the earliest of death, retransplant, trans-
plant nephrectomy, or initiation of or return to dialysis, was based 
on transplant program reporting to the respective registries. Death 
ascertainment was supplemented by linkages to other national da-
tabases in the United States4 and the United Kingdom. Details of 
ANZDATA auditing have been reported previously.5
Recipient race and primary renal diagnosis were missing for 33% 
and 38% of United Kingdom recipients, respectively. Ischemia time 
for deceased donor transplants was missing for 2.4%, 7.9%, 46.5%, 
and 26.8% of transplants in Australia, New Zealand, the United 
Kingdom, and the United States, respectively, and for living donor 
transplants for 1.5%, 0.5%, 20.7%, and 44.0%, respectively. In the 
United Kingdom, recipient race and ischemia time were not collected 
until 1998 and 2000, respectively. Donor cause of death was missing 
for 2.7% and 6.2% of Australia and New Zealand cases, respectively. 
The number of HLA mismatches was missing for 4.7% and 1.8% of 
transplants in Australia and New Zealand, respectively. For the re-
maining country and variable combinations, values were missing for 
no more than 1% of subjects (full list of covariates given below).
As recommended by Little et al,6,7 missing data were handled 
by multiple imputation using the sequential regression imputation 
method,8 implemented with the Impute module of the IVEware soft-
ware package.9 We performed 40 imputations for missing data. Model 
results from individual imputations were combined using SAS Proc 
MIAnalyze to calculate overall the effect estimates and significance 
levels presented in the paper.7 Results of models fitted from complete 
case data (Table S1) were very similar to those that used imputed data.
Descriptive statistics are given as median (quartile 1 to quartile 3) 
for continuous variables and as percentages for categorical factors.
Cox regression models were used to compare risk- adjusted 
graft failure among the study countries. Separate models were fit-
ted for 1 year (short- term) and long- term graft failure. The short- 
term graft failure model examined the time from transplantation 
to graft failure (as defined above), censored at the earlier of end of 
follow- up or 1- year posttransplantation. The long- term graft fail-
ure model was conditional on the recipient being alive with graft 
function at 1 year. Time at risk for the long- term model began at 1- 
year posttransplantation and continued to graft failure (as defined 
above), censored at the earlier of end of follow- up or end of study. 
In addition to the country indicators, covariates in the short- term 
and long- term models included recipient characteristics (age, sex, 
race, primary renal diagnosis), donor characteristics (age, sex), do-
nation type (living, donation after brain death, donation after circu-
latory determination of death), cause of donor death, relationship 
to recipient, total ischemia time, HLA mismatch, and year of trans-
plantation. Figures illustrating graft survival over time by country 
were produced using models stratified by country and presented 
for each country at study average covariate values. The short- 
term model revealed some evidence of nonproportional hazards 
in the country effects; country parameter estimates for this model 
should be interpreted as the average effects over the first post-
transplantation year. The long- term graft failure model showed no 
evidence of violation of the proportional hazards assumption.
To test the robustness of our long- term model within covari-
ate sub- cohorts, we tested whether country- specific hazard ratios 
for the long- term risk of graft failure varied across study subco-
horts defined by the levels or categories of each tested covariate. 
In each model, we examined the country- specific risk of graft fail-
ure restricted to a subcohort defined by a specific level or category 
of one covariate. This was repeated for each level of all covariates, 
with each model adjusted for all other covariates. Country- specific 
hazard ratio P- values were adjusted using the stepdown Bonferroni 
adjustment for multiple comparisons.10
We examined trends in country- specific hazard ratios over cal-
endar time with graft failure models that included country, year of 
transplant (continuous), and country- by- year interaction terms.
We explored the sensitivity of our results to the effect of poten-
tial unmeasured confounders using the method of Lin et al,11 depicted 
graphically according to Weintraub et al.12 This method allowed us 
to assess whether significant differences in country- specific risks of 
long- term graft failure could be explained by an unmeasured patient- 
level confounder with disparate prevalence across countries.
Statistical analyses were carried out using SAS version 9.4 (SAS 




There were 379 257 kidney transplants performed in the 4 countries 
from 1988 to 2014. Characteristics of the study cohort are shown 
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in Table 1. Median recipient age at transplantation was 48; 61% of 
recipients were male. Median recipient age and sex were consistent 
across countries, as were donor age and sex. The distribution of recip-
ient race varied considerably by country, as did other donor variables. 
Living donor organs were used for 36%, 33%, and 40% of transplants 
in the United States, Australia, and New Zealand, respectively, and for 
25% in the United Kingdom. The proportion of zero HLA- mismatched 
transplants was higher in the United States (8.8%) and the United 
Kingdom (9.4%) than in Australia (5.2%) and New Zealand (5.4%).
3.2 | One- year and conditional long- term graft 
failure models
Compared to the United States, the 1- year adjusted risk of kid-
ney graft failure was 22% and 29% higher in the United Kingdom 
and New Zealand, respectively (HR 1.22 and 1.29; each P < .001) 
(Figure 1A). The 1- year risk of graft failure in Australia was lower 
than in the United States (HR 0.90, P = .001).
In contrast to the 1- year results, the risk of long- term graft fail-
ure (conditional on function at 1 year) was significantly lower in 
Australia, New Zealand, and the United Kingdom compared to the 
United States, by 26%, 25%, and 26%, respectively (adjusted HR 
0.74, 0.75, and 0.74; each P < .001) (Figure 1B). Median graft survival 
times at the overall average covariate values were 11.2 years for the 
United States, compared to >14.7 years for Australia, New Zealand, 
and the United Kingdom.
3.3 | Long- term country- specific graft failure risk by 
covariate subcohorts
Subcohort models showed that the lower overall country- specific 
adjusted risks of long- term graft failure in Australia and the United 
Kingdom were mirrored by consistent results across individual 
covariate levels for most recipient, donor, and transplant factors 
(Table 2). For example, separate models for each primary renal di-
agnosis category showed that the risks of long- term graft failure 
in Australia and the United Kingdom were lower than the United 
States within each category (diabetes: HR = 0.84 Australia vs 
United States, HR = 0.60 United Kingdom vs United States; glo-
merulonephritis: HR = 0.79 Australia vs United States, HR = 0.83 
United Kingdom vs United States; other diagnosis HR = 0.74 
Australia vs United States, HR = 0.76 United Kingdom vs United 
States). These results suggest that the important effect heteroge-
neity in individual covariates by country was unlikely to have been 
responsible for the large overall differences in long- term graft fail-
ure rates. In one notable exception, the subcohort of recipients in 
the United States whose race was other than white or Asian (prin-
cipally but not exclusively African Americans) had significantly 
better long- term outcomes than their counterpart (principally 
but not exclusively Aboriginal recipients) in Australia. Subcohort 
models comparing New Zealand and the United States had limited 
statistical power due to small sample size, but followed the same 
patterns as Australia and the United Kingdom.
To examine whether the type of health care insurance (for 
United States recipients) disproportionately accounted for adverse 
United States outcomes, we ran 2 additional models comparing 
all recipients in the Australia, New Zealand, and United Kingdom 
countries to (1) the subset of United States recipients with private 
health care insurance and (2) those whose primary health care in-
surance was government- funded (Medicare/Medicaid). The risk of 
long- term graft failure for the recipient subsets in the United States 
in both cases was significantly higher (United States private insur-
ance: HR = 0.86, P < .001 Australia vs United States; HR = 0.86, 
P < .001 New Zealand vs United States; HR = 0.90, P < .001 United 
Kingdom vs United States; United States Medicare/Medicaid: 
HR = 0.63, P < .001 Australia vs United States; HR = 0.66, P < .001 
New Zealand vs United States; HR = 0.65, P < .001 United Kingdom 
vs United States).
3.4 | Time trend in country- specific graft failure risk
The risk of short- term graft failure decreased significantly over 
the 27- year cohort period (each within- country slope P < .001) 
(Figure 2A). In 1988, 1- year risk was significantly higher in New 
Zealand and the United Kingdom than in the United States (P < .001). 
Thereafter, a larger decrease in 1- year graft failure risk occurred 
over time in those countries than in the United States (United States 
HR = 0.94 per year, New Zealand HR = 0.92 per year; P = .08), such 
that the 1- year risk became equal to the United States by 2014. The 
rate of improvement in 1- year graft failure risk was not significantly 
different between the United States and Australia. The improve-
ment in 1- year risk of graft failure was smaller in the United Kingdom 
compared to the United States, although the effect size was modest 
(United States HR = 0.94 per year, United Kingdom HR = 0.95 per 
year, P < .001).
Long- term graft failure risk, conditional on function at 1 year, 
also improved in all 4 countries over time (each P < .001) (Figure 2B). 
The reduction in risk over time, compared to the United States, was 
slightly more marked in Australia (Australia HR = 0.961 per year, 
United States HR = 0.967 per year; P = .03) (Figure 2B). Long- term 
outcome remained worse in the United States throughout the period 
of study.
3.5 | Possibility of an unmeasured confounder
We examined whether the significantly higher risk of long- term 
graft failure after kidney transplant in the United States could be 
explained by residual confounding by unmeasured factors. To negate 
the observed country- specific differences, there would need to be a 
strong enough association between the unmeasured factor, and suf-
ficiently disparate prevalence of that confounder, to cause the upper 
95% confidence limit of the country- specific hazard ratio to cross 
1.0. Various combinations of effect sizes (hazard ratios) of a puta-
tive confounder and disparate prevalences in the recipients of com-
parator countries were tested. Figure 3 shows prevalence curves 
for Australia plotted across a range of United States prevalence and 
     |  1917MERION Et al.
TABLE  1 Characteristics of the study cohort
Characteristic median 
(Q1,Q3) or n (%)
Australia 




(n = 44 781)
United States 
(n = 318 423)
Total 
(n = 379 257)
Recipient age (y) 48 (35,57) 46 (32,57) 46 (33,57) 48 (36,59) 48 (35,58)
Recipient sex: male 8318 (61.2%) 1540 (62.3%) 27 746 (62.0%) 192 297 (60.4%) 229 901 (60.6%)
Recipient race
Asian 1088 (8.0%) 165 (6.7%) 3563 (8.0%) 14 939 (4.7%) 19 755 (5.2%)
White 11 343 (83.5%) 1748 (70.7%) 24 462 (54.6%) 179 142 (56.3%) 216 695 (57.1%)
Other 1111 (8.2%) 555 (22.5%) 2087 (4.7%) 124 314 (39.0%) 128 067 (33.8%)
Missing 40 (0.3%) 3 (0.1%) 14 669 (32.8%) 28 (<0.1%) 14 740 (3.9%)
Recipient diagnosis
Diabetes 1172 (8.6%) 262 (10.6%) 2878 (6.4%) 75 446 (23.7%) 79 758 (21.0%)
Glomerulonephritis 6231 (45.9%) 1105 (44.7%) 7104 (15.9%) 86 588 (27.2%) 101 028 (26.6%)
Other 6179 (45.5%) 1104 (44.7%) 18 003 (40.2%) 156 154 (49.0%) 181 440 (47.8%)
Missing 0 (0.0%) 0 (0.0%) 16 796 (37.5%) 235 (0.1%) 17 031 (4.5%)
Donor age (y) 46 (33,56) 41 (28,51) 46 (33,56) 38 (26,49) 40 (26,50)
Donor sex: male 7254 (53.4%) 1255 (50.8%) 23 489 (52.5%) 169 534 (53.2%) 201 532 (53.1%)
Donor type
Living 4540 (33.4%) 994 (40.2%) 11 060 (24.7%) 115 642 (36.3%) 132 236 (34.9%)
Deceased (brain death) 8224 (60.6%) 1455 (58.9%) 28 325 (63.3%) 188 502 (59.2%) 226 506 (59.7%)
Deceased (circulatory 
death)
818 (6.0%) 22 (0.9%) 5396 (12.0%) 14 279 (4.5%) 20 515 (5.4%)
Donor cause of death
Trauma 2910 (21.4%) 537 (21.7%) 7242 (16.2%) 90 852 (28.5%) 101 541 (26.8%)
Nontrauma 5765 (42.4%) 787 (31.8%) 26 327 (58.8%) 111 765 (35.1%) 144 644 (38.1%)
N/A (living donor) 4540 (33.4%) 994 (40.2%) 11 060 (24.7%) 115 642 (36.3%) 132 236 (34.9%)
Missing 367 (2.7%) 153 (6.2%) 152 (0.3%) 164 (0.1%) 836 (0.2%)
Relationship to recipient
Sibling 1110 (8.2%) 271 (11.0%) 3019 (6.7%) 35 949 (11.3%) 40 349 (10.6%)
Biologically related 
nonsibling
1901 (14.0%) 392 (15.9%) 4581 (10.2%) 42 954 (13.5%) 49 828 (13.1%)
Biologically unrelated 1529 (11.3%) 331 (13.4%) 3455 (7.7%) 35 857 (11.3%) 41 172 (10.9%)
N/A (deceased donor) 9042 (66.6%) 1477 (59.8%) 33 721 (75.3%) 202 781 (63.7%) 247 021 (65.1%)
Missing 0 (0.0%) 0 (0.0%) 5 (<0.1%) 882 (0.3%) 887 (0.2%)
Total ischemia time
Living donor 2 (1,3) 3 (1,4) 3 (2,4) 2 (1,2) 2 (1,3)
Deceased donor 14 (11,18) 16 (12,19) 16 (13,20) 19 (13,25) 18 (13,25)
Number of HLA mismatches
0 700 (5.2%) 134 (5.4%) 4191 (9.4%) 28 037 (8.8%) 33 062 (8.7%)
1 1307 (9.6%) 240 (9.7%) 4926 (11.0%) 14 750 (4.6%) 21 223 (5.6%)
2 2990 (22.0%) 572 (23.1%) 11 901 (26.6%) 35 416 (11.1%) 50 879 (13.4%)
3 2893 (21.3%) 620 (25.1%) 13 289 (29.7%) 66 119 (20.8%) 82 921 (21.9%)
4 1963 (14.5%) 466 (18.9%) 6479 (14.5%) 66 991 (21.0%) 75 899 (20.0%)
5 2053 (15.1%) 305 (12.3%) 2729 (6.1%) 69 719 (21.9%) 74 806 (19.7%)
6 1044 (7.7%) 90 (3.6%) 921 (2.1%) 34 644 (10.9%) 36 699 (9.7%)
Missing 632 (4.7%) 44 (1.8%) 345 (0.8%) 2747 (0.9%) 3768 (1.0%)
(Continues)
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hazard ratios. These represent combinations where the upper 95% 
confidence limit of the hazard ratio for recipients in Australia versus 
the United States (0.77) would be elevated to 1.00 by inclusion of 
the unmeasured confounder. Given the existence of an unmeasured 
factor with a hazard ratio of 2.0, Figure 3 shows that the observed 
difference between the United States and Australia could be ex-
plained only by a factor that was at least 31 percentage points more 
prevalent in the United States than Australia, for example, 36% vs 
5% or lower, respectively. For the United Kingdom, the difference 
in prevalence compared to the United States would need to be at 
least 35 percentage points to explain the difference in long- term 
graft survival, whereas the difference for New Zealand would need 
to be at least 26 percentage points. For unmeasured confounders 
with hazard ratios closer to 1.0, the corresponding required disparity 
in prevalence was even greater.
4  | DISCUSSION
Kidney transplantation is an effective treatment for end- stage 
renal disease, but a search for opportunities to improve long- term 
allograft function deserves attention. With the goal to learn from 
differences in outcomes, this collaborative study used detailed ob-
servational data reported to well- established transplant registries on 
3 continents to assess differences in kidney graft outcomes across 
4 countries using a uniform analytical methodology. We found that 
recipients in the United States had a lower risk of graft failure in the 
first posttransplantation year compared to patients transplanted in 
the United Kingdom and New Zealand (but not significantly differ-
ent than Australians). Although 1 year is the traditional short- term 
milepost for assessing outcome in kidney transplantation, long- term 
outcome is a more relevant patient- centered metric. We found that 
the risk of long- term graft failure among those whose grafts were 
functioning at 1 year was approximately 25% lower in Australia, 
New Zealand, and the United Kingdom than in the United States. In 
patient- centered terms, this represents 3 years of forfeited kidney 
graft function time for the average recipient in the United States.
To evaluate the possibility that the striking differences in over-
all graft failure risk—despite extensive statistical adjustment for 
confounding covariates—were driven by heterogeneity of effects, 
we leveraged the large size of our cohort to focus on subcohorts. 
Compared to the United States, lower long- term risk was consistently 
Characteristic median 
(Q1,Q3) or n (%)
Australia 




(n = 44 781)
United States 
(n = 318 423)
Total 
(n = 379 257)
Era of transplant
1988- 1994 2697 (19.9%) 522 (21.1%) 10 032 (22.4%) 59 765 (18.8%) 73 016 (19.3%)
1995- 1998 1605 (11.8%) 365 (14.8%) 5624 (12.6%) 40 653 (12.8%) 48 247 (12.7%)
1999- 2002 1809 (13.3%) 381 (15.4%) 5475 (12.2%) 47 986 (15.1%) 55 651 (14.7%)
2003- 2006 2023 (14.9%) 342 (13.8%) 6071 (13.6%) 55 511 (17.4%) 63 947 (16.9%)
2007- 2010 2521 (18.6%) 426 (17.2%) 7950 (17.8%) 57 429 (18.0%) 68 326 (18.0%)
2011- 2014 2927 (21.6%) 435 (17.6%) 9629 (21.5%) 57 079 (17.9%) 70 070 (18.5%)
TABLE  1  (Continued)
F IGURE  1 Adjusted graft survival 
by country for (A) 1- year follow- up 
(n = 379 257, graft failures = 33 981) 
and (B) long- term follow- up conditional 
on being alive with a functioning graft 
at 1 year (n = 318 048, graft failures = 
119 322). Survival curves for each country 
were generated using average covariate 
values of the entire study cohort. Note 
that in panel (A) the y- axis has a break that 
zooms in on the upper part of the range to 
make the differences in short- term graft 
survival more easily visible
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demonstrated in Australia, New Zealand, and the United Kingdom 
across almost all tested subcohorts of recipient and donor demo-
graphics, donor source, and transplant characteristics (eg, HLA mis-
match). The result for the heterogeneous subcohort of recipient race 
other than white or Asian was an exception. Nonwhite, non- Asian 
recipients in Australia (principally Aboriginal) had significantly worse 
outcome than their nonwhite, non- Asian counterpart (overwhelm-
ingly African American) in the United States. Although it is well 
established that Australian Aboriginal kidney transplant recipients 
have worse outcomes than nonindigenous Australians13,14 and that 
African Americans have worse outcomes than whites in the United 
States,15 we were not able to directly compare results between 
Native Americans in the United States and indigenous Australians 
due to small sample sizes and insufficient specificity of the under-
lying data, respectively. Interpretation of this finding is challeng-
ing, as there are many potential differences between indigenous 
Australians and African Americans (eg, socioeconomics, pharmacog-
enomics, social systems, access to care) that may explain the dispa-
rate outcomes.
It was not surprising that both 1- year and long- term outcomes 
significantly improved in each country over the quarter century 
encompassed by this study. This is consistent with improvements 
in kidney transplantation results worldwide. One- year outcomes, 
which were significantly better in the United States compared to the 
United Kingdom and New Zealand in the early years of the study, 
were similar in all 4 countries by 2014. For long- term outcomes, the 
average reduction in graft failure risk ranged from 2.7% to 3.9% per 
year across the 4 countries.
The rates of improvement over time in long- term outcome in the 
United Kingdom and New Zealand did not differ significantly from that 
in the United States, whereas the rate of improvement in Australia was 
significantly higher. Consequently, country- specific disparities in long- 
term outcome were sustained over time, even in the most recent years 
of the study; long- term outcome in the United States remains worse 
than in the United Kingdom, Australia, and New Zealand.
We had access to rich clinical datasets from all 4 countries; the 
3 registries selected for this study had comparable data collec-
tion methods, analytical conventions, and longitudinal follow- up. 
F IGURE  2 Trend in risk of graft failure over calendar time 1988- 2014 by country (A) hazard ratio (HR) of graft failure within the first year 
and (B) long- term HR of graft failure conditional on being alive with a functioning graft at 1 year. The reference (HR = 1.0) is the risk of graft 
failure in 1988 in the United States
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Nonetheless, unmeasured confounders could have accounted for the 
observed differences in outcomes. It has been postulated that kidney 
transplant recipients in the United States may have more comorbid 
conditions that contribute to graft failure than recipients elsewhere.16 
If such data were available, and if their inclusion as adjustment co-
variates negated the observed excess long- term graft failure risk in 
the United States patients, it would explain why results were worse 
in the United States. We did not have uniform data on panel reac-
tive antibody levels, but the majority of first- time kidney transplant 
recipients are unsensitized. In the current study, we adjusted for the 
presence or absence of diabetes mellitus, but we did not have access 
to patient- level data on cardiovascular disease, peripheral vascular 
disease, or other conditions. Conceptually, however, one or more vari-
ables important enough to negate our findings would have required, 
in aggregate, a very large effect size, combined with highly disparate 
prevalence in United States and non- United States recipients. This 
seems unlikely from a clinical standpoint, given the relative stringency 
of kidney transplant recipient eligibility assessment. As a further step, 
our study included a specific quantification of the possibility of un-
measured confounding using a method reported in other observa-
tional studies12; the results cast doubt on unmeasured confounding 
as the explanation for country- specific differences in outcome.
Limitations of the present study include the possibility of under-
ascertainment of graft failure or death. However, each of the regis-
tries used supplemental data sources to capture dialysis or death. 
Race was based on registry files and may not be patient reported, 
a common problem in most clinical studies. Data on race were not 
available for early years in the United Kingdom; however, sensitivity 
analyses using complete case data were consistent with the main 
analyses performed using multiple imputation.
International studies of chronic diseases can reveal differ-
ences in outcomes that result from country- specific medical prac-
tice patterns or healthcare delivery systems that are exogenous 
to patient characteristics. In the Dialysis Outcomes and Practice 
Patterns Study, an international prospective observational study of 
hemodialysis patients, detailed adjustment for multiple comorbid 
conditions failed to explain excess mortality among United States 
dialysis patients, whereas more than half of the excess was ac-
counted for by country- specific differences in vascular access prac-
tices.17 In kidney transplantation, time- limited insurance coverage 
for immunosuppressive medication may mediate impaired long- 
term outcome in low- income recipients in the United States18 and 
income- based outcome disparities were ameliorated after a 3- year 
coverage limitation ended.19 In each of the countries other than the 
United States studied here, health insurance coverage and medica-
tion availability are universal. Our sub- analysis showed that recip-
ients in the United States with private health care insurance and 
government- funded health care insurance (Medicare/Medicaid) 
each had significantly higher risks of long- term graft failure than 
recipients in Australia, New Zealand, and the United Kingdom.
Aside from healthcare insurance, there are other differences 
in health care systems and potentially identifiable differences in 
F IGURE  3 Effect of potential unmeasured confounder. The graph shows how large an effect and/or disparity in prevalence of a single 
confounder would need to be to explain the superior long- term graft outcome in Australia compared to the United States. For a given 
prevalence in Australia (each line represents a given prevalence) and in the United States (depicted on the x- axis), the values on the y- axis 
represent the hazard ratios for graft failure that would be required to account for the difference in the observed risk of graft failure. The dot 
in the figure represents the example of an unmeasured confounder with a hazard ratio of 2.0. A prevalence of 36% in the United States and 
5% or less in Australia would be necessary to negate the observed difference in long- term outcome. Adapted from Weintraub et al12
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posttransplantation care practice patterns that would be candidates 
to study as factors leading to disparate kidney transplant outcomes 
around the world. Focused studies of transplant center practices (eg, 
the extent to which uniform patient care guidelines are used; the 
timing and extent of return of care responsibility from the transplant 
center to local physicians; differences in immunosuppression prac-
tices) are needed to better understand the differences in outcome 
we observed and to suggest interventions in posttransplantation 
care to test as best practices.
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